Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 879-886

  Rogenhofer, Sebastian ^a   Kahl, Philip ^a   Holzapfel, Stefanie ^a   Von Ruecker, Alexander ^b   Mueller, Stefan C ^a   Ellinger, Jörg ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

H3K9; H4K20; Histone; Methylation; Renal cell carcinoma

Indexed keywords

HISTONE H3; HISTONE H3 LYSINE 27; HISTONE H3 LYSINE 9; HISTONE H4; HISTONE H4 LYSINE 20; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MALE; ONCOCYTOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SARCOMATOID RENAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HISTONES; HUMANS; KIDNEY NEOPLASMS; MALE; METHYLATION; MIDDLE AGED; PROGNOSIS;

EID: 84858788347     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Siegel R, XU J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60(5): 277-300, 2010.
2. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E and Zbar B: The Heidelberg Classification of renal cell tumours. J Pathol 183(2): 131-133, 1999.
3. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS and Pantuck AJ: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23(12): 2763-2771, 2005. (Pubitemid 46179466)
4. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M and Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435(7046): 1262-1266, 2005. (Pubitemid 40943093)
5. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM and Ellis IO: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69(9): 3802-3809, 2009.
6. Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA and Rodriguez JA: Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 25(28): 4358-4364, 2007. (Pubitemid 350013840)
7. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M and Oya M: Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 180(3): 1131-1136, 2008.
8. Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Di Primio R, Montironi R and Muzzonigro G: Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. J Cell Mol Med 13(8B): 2115-2121, 2009.
9. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L and Kurdistani SK: Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 174(5): 1619-1628, 2009.
10. Ellinger J, Kahl P, Mertens C, Rogenhofer S, Hauser S, Hartmann W, Bastian PJ, Buttner R, Muller SC and von Ruecker A: Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer 127(10): 2360-2366, 2010.
11. Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, Walter B, Hofstadter F, Buttner R, Muller SC, Bastian PJ and von Ruecker A: Global levels of histone modifications predict prostate cancer recurrence. Prostate 70(1): 61-69, 2010.
12. Kurdistani SK.: Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer 97(1): 1-5, 2007.
13. Mosashvilli D, Kahl P, Mertens C, Holzapfel S, Rogenhofer S, Hauser S, Buttner R, Von Ruecker A, Muller SC and Ellinger J: Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci 101(12): 2664-2669, 2010.
14. Rogenhofer S, Kahl P, Mertens C, Hauser S, Hartmann W, Buttner R, Muller SC, von Ruecker A and Ellinger J: Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int 109(3): 459-465, 2012.
15. Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS and Kung AL: Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 106(11): 4260-4265, 2009.
16. Pollard PJ, Loenarz C, Mole DR, McDonough MA, Gleadle JM, Schofield CJ and Ratcliffe PJ: Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J 416(3): 387-394, 2008.
17. Johnson AB, Denko N and Barton MC: Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. Mutat Res 640(1-2): 174-179, 2008.
18. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T and Esteller M: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4): 391-400, 2005.
19. Eden A, Gaudet F, Waghmare A and Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300(5618): 455, 2003. (Pubitemid 36444319)
20. Heng DY and Choueiri TK: Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw 7(6): 659-665, 2009.
21. Fritzsche FR, Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M and Kristiansen G: Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8: 381, 2008.
22. Mahalingam D, Medina EC, Esquivel JA, 2nd, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ and Nawrocki ST: Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 16(1): 141-153, 2010.
23. Lee MG, Wynder C, Schmidt DM, McCafferty DG and Shiekhattar R: Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 13(6): 563-567, 2006.